DK0706507T3 - Salmeterolxinafoat med kontrolleret partikelstørrelse - Google Patents

Salmeterolxinafoat med kontrolleret partikelstørrelse

Info

Publication number
DK0706507T3
DK0706507T3 DK94918982T DK94918982T DK0706507T3 DK 0706507 T3 DK0706507 T3 DK 0706507T3 DK 94918982 T DK94918982 T DK 94918982T DK 94918982 T DK94918982 T DK 94918982T DK 0706507 T3 DK0706507 T3 DK 0706507T3
Authority
DK
Denmark
Prior art keywords
pct
particle size
salmeterol xinafoate
controlled particle
sec
Prior art date
Application number
DK94918982T
Other languages
English (en)
Inventor
Peter York
Mazen Hanna
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0706507T3 publication Critical patent/DK0706507T3/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
    • B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Investigating Or Analyzing Materials By The Use Of Fluid Adsorption Or Reactions (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
DK94918982T 1993-07-01 1994-06-30 Salmeterolxinafoat med kontrolleret partikelstørrelse DK0706507T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939313650A GB9313650D0 (en) 1993-07-01 1993-07-01 Method and apparatus for the formation of particles
PCT/GB1994/001425 WO1995001324A1 (en) 1993-07-01 1994-06-30 Salmeterol xinafoate with controlled particle size

Publications (1)

Publication Number Publication Date
DK0706507T3 true DK0706507T3 (da) 2000-04-10

Family

ID=10738146

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94918982T DK0706507T3 (da) 1993-07-01 1994-06-30 Salmeterolxinafoat med kontrolleret partikelstørrelse

Country Status (20)

Country Link
US (1) US5795594A (da)
EP (1) EP0706507B1 (da)
JP (1) JP3839042B2 (da)
CN (1) CN1062854C (da)
AT (1) ATE184870T1 (da)
AU (1) AU684795B2 (da)
BR (1) BR9406995A (da)
CA (1) CA2165830C (da)
DE (1) DE69420844T2 (da)
DK (1) DK0706507T3 (da)
ES (1) ES2138085T3 (da)
FI (1) FI956343A (da)
GB (1) GB9313650D0 (da)
GR (1) GR3032065T3 (da)
HK (1) HK1004216A1 (da)
HU (1) HUT73733A (da)
NO (1) NO304940B1 (da)
NZ (1) NZ267696A (da)
RU (1) RU2136655C1 (da)
WO (1) WO1995001324A1 (da)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576264B1 (en) * 1995-10-17 2003-06-10 Skyepharma Canada Inc. Insoluble drug delivery
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
GB9622173D0 (en) 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
GB9806462D0 (en) * 1998-03-26 1998-05-27 Glaxo Group Ltd Improved compositions for inhalation
GB9808802D0 (en) * 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
GB9810559D0 (en) * 1998-05-15 1998-07-15 Bradford Particle Design Ltd Method and apparatus for particle formation
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
SE9804001D0 (sv) * 1998-11-23 1998-11-23 Astra Ab New process
EP1185248B1 (en) * 1999-06-09 2012-05-02 Robert E. Sievers Supercritical fluid-assisted nebulization and bubble drying
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB9915975D0 (en) * 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
JP2003507410A (ja) * 1999-08-25 2003-02-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 乾燥粉末製剤からの放出調節
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
ATE343374T1 (de) * 1999-09-11 2006-11-15 Glaxo Group Ltd Fluticasonpropionat arzneizubereitung
FR2803538B1 (fr) * 1999-12-15 2002-06-07 Separex Sa Procede et dispositif de captage de fines particules par percolation dans un lit de granules
AU2729101A (en) 1999-12-21 2001-07-03 Rxkinetix, Inc. Particulate drug-containing products and method of manufacture
US6761909B1 (en) 1999-12-21 2004-07-13 Rxkinetix, Inc. Particulate insulin-containing products and method of manufacture
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
US8551526B2 (en) * 2000-11-03 2013-10-08 Board Of Regents, The University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US6756062B2 (en) 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
WO2002053190A2 (en) 2000-12-29 2002-07-11 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
IL157346A0 (en) * 2001-02-26 2004-02-19 Dompe Spa Apparatus and method for micron and submicron particle formation
WO2003006223A1 (en) * 2001-07-10 2003-01-23 University Technology Corporation Devices and methods for the production of particles
GB0117403D0 (en) * 2001-07-17 2001-09-05 Pharmacia & Upjohn Spa Solvent-free crystalline anthracycline derivatives
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
EA006064B1 (ru) * 2001-10-10 2005-08-25 Бёрингер Ингельхайм Фармасьютиклз, Инк. Способ обработки порошков сжиженными газами
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
ES2415654T3 (es) * 2001-11-20 2013-07-26 Civitas Therapeutics, Inc. Composiciones particuladas mejoradas para suministro pulmonar
SI1458360T1 (sl) 2001-12-19 2011-08-31 Novartis Ag Pulmonalno dajanje aminoglikozidov
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
AU2003218308B2 (en) * 2002-03-20 2006-07-20 Advanced Inhalation Research, Inc. hGH (human growth hormone) formulations for pulmonary administration
US20050163725A1 (en) * 2002-03-20 2005-07-28 Blizzard Charles D. Method for administration of growth hormone via pulmonary delivery
WO2003090715A2 (en) * 2002-04-25 2003-11-06 Nektar Therapeutics Uk Ltd Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
WO2004056341A1 (en) * 2002-12-19 2004-07-08 Baxter International, Inc. Process for preparing pharmaceutical formulations using supercritical fluids
US20040152720A1 (en) * 2002-12-20 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
DE10351663A1 (de) * 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat
JP4808970B2 (ja) * 2002-12-30 2011-11-02 ネクター セラピューティクス 噴霧乾燥システム
US6915966B2 (en) * 2003-01-29 2005-07-12 Specialty Minerals (Michigan) Inc. Apparatus for the gunning of a refractory material and nozzles for same
MY147403A (en) * 2003-04-29 2012-11-30 Kowa Co Composition containing medicine extremely slightly solube in water and method for preparation thereof
MXPA05011343A (es) 2003-05-08 2005-12-12 Nektar Therapeutics Uk Ltd Materiales particulados.
JP4206317B2 (ja) * 2003-09-10 2009-01-07 花王株式会社 有機板状粒子の製造方法
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
DE602005009012D1 (de) * 2004-10-12 2008-09-25 Generics Uk Ltd Rmulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US7854397B2 (en) * 2005-01-21 2010-12-21 Specialty Minerals (Michigan) Inc. Long throw shotcrete nozzle
EP1904219A4 (en) 2005-07-15 2011-07-27 Map Pharmaceuticals Inc METHOD FOR FORMING PARTICLES
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
EP1919923A1 (en) * 2005-08-17 2008-05-14 Synthon B.V. A process for making olanzapine form i
KR20080077147A (ko) * 2005-12-07 2008-08-21 와이어쓰 결정성 라파마이신의 제조 방법 및 시차 주사 열량계를사용하는 라파마이신 화합물의 결정화도의 측정 방법
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
CN1973812B (zh) * 2006-11-03 2010-12-08 谭登平 一种将超临界二氧化碳萃取物固体粉末化的方法
AU2008214205B2 (en) 2007-02-11 2014-04-24 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
EP2127641A1 (en) 2008-05-26 2009-12-02 Inke, S.A. Micronisable form of salmeterol xinafoate
WO2012032546A2 (en) 2010-09-08 2012-03-15 Cadila Healthcare Limited Process for the preparation of salmeterol and its intermediates
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
US9908062B2 (en) 2012-11-20 2018-03-06 Andrew Paul Joseph Extraction apparatus and method
WO2014081881A2 (en) * 2012-11-20 2014-05-30 Andrew Paul Joseph Fluid-based extractor
JP2021141003A (ja) * 2020-03-07 2021-09-16 エムテックスマート株式会社 ２次電池の製造方法または２次電池
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744329A1 (de) * 1987-12-28 1989-07-06 Schwarz Pharma Gmbh Verfahren zur herstellung einer mindestens einen wirkstoff und einen traeger umfassenden zubereitung
ES2079210T3 (es) * 1991-12-12 1996-01-01 Glaxo Group Ltd Formulacion farmaceutica de aerosol.
US5509404A (en) * 1994-07-11 1996-04-23 Aradigm Corporation Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values

Also Published As

Publication number Publication date
EP0706507A1 (en) 1996-04-17
ES2138085T3 (es) 2000-01-01
ATE184870T1 (de) 1999-10-15
NO955355D0 (no) 1995-12-29
NZ267696A (en) 1997-11-24
CN1062854C (zh) 2001-03-07
NO304940B1 (no) 1999-03-08
CA2165830C (en) 2005-04-26
CA2165830A1 (en) 1995-01-12
CN1129932A (zh) 1996-08-28
GB9313650D0 (en) 1993-08-18
HK1004216A1 (en) 1998-11-20
DE69420844T2 (de) 2000-03-16
US5795594A (en) 1998-08-18
HU9503772D0 (en) 1996-02-28
AU684795B2 (en) 1998-01-08
WO1995001324A1 (en) 1995-01-12
DE69420844D1 (de) 1999-10-28
GR3032065T3 (en) 2000-03-31
HUT73733A (en) 1996-09-30
RU2136655C1 (ru) 1999-09-10
NO955355L (no) 1996-02-29
BR9406995A (pt) 1996-09-10
AU7007094A (en) 1995-01-24
FI956343A0 (fi) 1995-12-29
FI956343A (fi) 1996-02-15
EP0706507B1 (en) 1999-09-22
JPH08512047A (ja) 1996-12-17
JP3839042B2 (ja) 2006-11-01

Similar Documents

Publication Publication Date Title
DK0706507T3 (da) Salmeterolxinafoat med kontrolleret partikelstørrelse
DE69936515D1 (de) Aerosolformulierungen von salmeterol xinafoate
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
DE69213010D1 (de) Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden.
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
IT8903526A0 (it) Metodo e dispositivo per l'avanzamento, in successione, di prodotti appiattiti
ITMO920035A0 (it) Flacone contagocce particolarmente per prodotti farmaceutici attivabili all'uso per miscelare
ES2161768T3 (es) Medicamento encapsulado.
ZA976967B (en) Device and process for separating magnetic materials from pharmaceutical preparations, their starting or intermediate products, as well as agents that are produced with the of said device.
ATE325803T1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
IL88971A0 (en) Disubstituted pyridines,their preparation and pharmaceutical compositions containing them
DE69327812D1 (de) Arsen-enthaltende arzneimittel zur behandlung des chronischen ermüdungssyndroms
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
DK0654028T3 (da) 3- og 5-substituerede 1,2,3,4-oxatriazol-5-iminforbindelser og fremgangsmåde til fremstilling deraf, farmaceutisk præparat indeholdende disse forbindelser samt forbindelsernes anvendelse til fremstilling af lægemidler
IT1239273B (it) Procedimento di preparazione di aromi naturali al tartufo e prodotti ottenuti.
IT1228902B (it) Procedimento ed impianto per la preparazione di prodotti farmaceutici in genere.
DK8291D0 (da) Praeparat omfattende en aktiv bestanddel, fortrinsvis i pulver- eller partikelform, samt en baerer for den aktive bestanddel og fremgangsmaade til fremstilling af et saadant praeparat
ATE155136T1 (de) Neue bishispidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
IT1320832B1 (it) Procedimento e impianto per il trattamento di prodotti di uovo esimili, destinati all'uso alimentare.
TH14468A (th) " วิธีการดำเนินกรรมวิธีกับมวลชีวภาพประเภทลิกโนเซลลูโลส "
DE60210268D1 (de) Verfahren zur herstellung von 7alpha,11beta-dimethyl-17beta-hydroxyestra-4, 14-dien-3-one, dessen 17-ester und pharmazeutische zubereitungen die sie enthalten
IT1282561B1 (it) Valvola per il trattamento di prodotti in pezzi fragili o in polvere.
IT1228310B (it) Impianto di sterilizzazione per sostanze alimentari in particelle.
GEP19991586B (en) Pharmaceutical Formulation
IT8806983V0 (it) Gruppo disgregatore, trinciatore, miscelatore e impastatore di alimenti per allevamenti zootecnici o per il trattamento di materiali in campo industriale.